Chen, Kai-Bo
Wu, Zhi-Wei
Wang, Jun
Zhu, Ling-Hua
Jin, Xiao-Li
Chen, Guo-Feng
Kang, Mu-Xing
Huang, Yi
Zhang, Hang
Lin, Le-Le
Shi, Di-Ke
Wu, Dan
Chen, Jian-Feng
Chen, Jian
Zhao, Zhi-Qing
Funding for this research was provided by:
Zhejiang Provincial Key Project of Research and Development Fund (2019C03043)
National Science and Technology Major Special Project for New Drug Development (2018ZX09201016)
Natural Science Foundation of Zhejiang Province (LY19H160042)
Basic Public Welfare Research Project of Zhejiang Province (LGD19H160004, LGF21H030005)
Clinical Research Fund of Zhejiang Medical Association (2018ZYC-A118)
Article History
Received: 26 June 2021
Accepted: 15 February 2022
First Online: 3 March 2022
Declarations
:
: This trial will be conducted according to the standards of the International Committee on Harmonization on Good Clinical Practice and the Declaration of Helsinki. This study protocol with written informed consent forms was peer-reviewed and approved by the Medical Ethics Committees of the Second Affiliated Hospital of Zhejiang University, School of Medicine (approval number 2020-454), and it was approved by the Chinese Clinical Trial Registry (approval number ChiCTR2000033965). Informed consent will be obtained from all participants.
: Written informed consent for publication will be obtained from all participants.
: The authors declare that they have no competing interests.